This move is archived. Current quotes and coverage live on the stock page.
Follow PCRX
PharmaCorp Rx Inc. faced a significant drop in its stock price today, closing down nearly 15%.
In the latest trading session, PharmaCorp Rx Inc. (PCRX.V) saw its stock price tumble by 14.66%, closing at CA$0.49. This decline raises concerns among investors about the company's stability and future performance, especially since there wasn't any major news to explain the downturn.
Investor takeaway: Investors should closely monitor PharmaCorp's financial health and market conditions, as today's drop may signal deeper issues that need addressing.
PharmaCorp Rx Inc.
PCRX.V
PCRX.V
PharmaCorp Rx Inc.
WealthAwesomeMarket cap
$79.78M
52W high
$0.58
52W low
$0.38
1W change
-3.57%
Beta
-3.95
Analyst Price Targets
Based on analyst covering PCRX · as of Sep 17, 2026
Wall Street analysts forecast PCRX stock price to rise 64.6% over the next 12 months.
Consensus
BullishBased on avg. target vs last close (formal rating unavailable for Canadian listings)
Avg. Target
C$0.67
+64.6% Upside
Current Price
C$0.41
Last close
Targets are snapshotted when they change. Unchanged figures keep their original date. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on PCRX's historical volatility
30-Day Vol
43.8%
Annualized
90-Day Vol
51.6%
Annualized
Trend (90d)
-50.0%
Annualized drift
90d Mean
C$0.34
Expected price
| Horizon | Expected | 68% Range (1σ) |
|---|---|---|
| 30 trading days | C$0.38 | C$0.33 – C$0.44 |
| 60 trading days | C$0.36 | C$0.29 – C$0.45 |
| 90 trading days | C$0.34 | C$0.26 – C$0.44 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
Bull case
Despite today’s setback, PharmaCorp has reported growth in prescription volumes and has plans for expansion. If managed well, these factors could lead to a recovery.
Bear case
The significant drop in stock price without any accompanying news might indicate underlying issues that could affect investor confidence and future performance.
Market Reaction
The 14.66% drop in PharmaCorp's stock price is alarming, especially since it comes without any significant news to explain the decline. Investors might be reacting to broader market trends or concerns about the company's operational strategies.
Financial Performance Overview
PharmaCorp has recently reported growth in its prescription volumes and sales. However, the current market response suggests that investors are wary of the company’s profitability, given its negative profit margin of -6.71%. Continuous scrutiny of financial results will be essential for maintaining investor confidence.
Looking Ahead
As PharmaCorp Rx Inc. navigates this challenging time, investors should keep an eye on upcoming financial reports and strategic announcements. The company's expansion plans may provide a pathway to recovery, but today's performance highlights the need for cautious optimism.
Best next step
Keep exploring this topic
If you want to go deeper, these are the most useful follow-up pages and tools for this topic.
Broker comparison
Best trading platforms in Canada
Compare $0-commission brokers before you act on a ticker story.
Safe cash
Best GIC rates in Canada
If the story makes you want to de-risk, compare guaranteed rates next.
HISA roundup
Best high-interest savings accounts
Keep dry powder in a no-fee savings account instead of chequing.
TFSA room
Check TFSA contribution room
Shelter the next contribution before you buy.
Wealth Awesome
Timely coverage of Canadian stocks, earnings, dividends, and market movers for DIY investors. Stories are checked against exchange data and public filings.
View Full Profile →✅ Reviewed by Certified Financial Professionals
This content has been reviewed by CFA® charterholders and Certified Financial Planners (CFP®) with over a decade of experience in Canadian financial markets. All information is fact-checked against official Canadian sources and regulations.
Why these credentials matter: CFA® charterholders complete 900+ hours of rigorous study in investment analysis and ethics. CFP® professionals are held to the highest standards of financial planning competency and fiduciary duty in Canada.
⚠️ Professional Disclaimer
This content is for educational purposes only and should not be considered personalized financial advice. While our team brings professional expertise, individual circumstances vary. For personalized guidance, consult with a qualified financial advisor, tax professional, or mortgage specialist.
